July 2026– date –
-
Strategic Capital Influx in Gene Therapy: Pfizer Invests in CRISPR Biotech, AstraZeneca Strengthens China Cell Therapy Capabilities
BioPharma Dive USA Overview The gene therapy sector is experiencing a surge in strategic funding and M&A activities from major pharmaceutical companies. Pfizer has invested in CRISPR biotech Caribou Biosciences, while AstraZeneca pla... -
Biopharma M&A Accelerates in H1 2026: Eli Lilly Leads with Over $25 Billion Spend as Big Pharma Bolsters Pipelines
BioPharma Dive USA Overview Biopharmaceutical M&A activity significantly accelerated in the first half of 2026, with over 50 deals transacted. Eli Lilly was notably active, spending over $25 billion and solidifying its position as a ... -
Capricor Therapeutics to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Conference
GlobeNewswire (via Capricor Therapeutics) USA Overview Capricor Therapeutics announced it will present crucial clinical data on Deramiocel, its lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD), at the PPMD 2026 Annual Co... -
FDA Issues Over Six Warning Letters for Unapproved Exosome Therapies in US, Citing Illegal Sales and Unsubstantiated Claims (2024-2026)
Medical Spa Locator USA Overview As of June 2026, no injectable exosome products have received FDA approval in the United States. The FDA has issued over six warning letters between 2024 and 2026 to manufacturers and distributors selling... -
Australian iCamuno Biotherapeutics Launches Clinical Trial for Parkinson’s with ‘Hypoimmune Neural Cell Therapy’ Avoiding Immunosuppression
News Hub (Australia) Australia Overview Supported by A$4.6 million from the Australian government's Medical Research Future Fund, iCamuno Biotherapeutics has initiated a five-year research program to evaluate a novel stem cell therapy fo... -
FDA Approves Orca-T, First Regulatory T-Cell Therapy to Improve Chronic GVHD-Free Survival in Blood Cancer Patients Undergoing Allogeneic HSCT
American Society of Clinical Oncology (ASCO) Post USA Overview The US FDA has approved Orca-T (Tregzi, Orca Bio), the first regulatory T-cell (Treg)-based immunotherapy to improve chronic graft-versus-host disease (GVHD)-free survival in... -
Fate Therapeutics to Present iPSC-Derived Cell Immunotherapy Pipeline Progress at Investor Conferences
Fate Therapeutics, Inc. USA Overview Fate Therapeutics announced its participation in several upcoming investor conferences during Q3 2026. The clinical-stage biopharmaceutical company focuses on developing innovative 'off-the-shelf' iPS... -
A2 Biotherapeutics’ CAR T-Cell Therapy A2B543 Receives FDA Fast Track Designation for Advanced Solid Tumors
OncLive USA Overview A2 Biotherapeutics Inc.'s autologous CAR T-cell therapy, A2B543, has been granted FDA Fast Track designation for adults with recurrent unresectable, locally advanced, or metastatic solid tumors who are HLA-A*02 posit... -
China’s NMPA Grants World’s First Approval for Solid Tumor CAR T-Cell Therapy Satri-cel Targeting CLDN18.2 Positive Gastric Cancer
OncLive USA Overview OncLive's June 2026 GI oncology regulatory roundup highlights China's NMPA approval of CARsgen Therapeutics' satricabtagene autoleucel (satri-cel), the first solid tumor CAR T-cell therapy for Claudin18.2-positive ad... -
Cellares’ Cell Shuttle Platform Accepted into FDA’s Inaugural Manufacturing PreCheck Cohort, First and Only Cell Therapy Platform to Receive Designation
BioSpace USA Overview Cellares announced its acceptance into the FDA's inaugural 'Manufacturing PreCheck Pilot Program,' as the sole cell therapy platform among seven companies nationwide. Its automated, end-to-end Cell Shuttle platform ...
